New hope for advanced liver cancer: particle beam plus immunotherapy trial launches

NCT ID NCT06828380

Recruiting now Disease control Sponsor: National Cancer Center, Korea Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II study tests whether adding particle beam radiation therapy to standard immunotherapy can help people with advanced liver cancer that has spread into major blood vessels. About 128 adults with unresectable or metastatic hepatocellular carcinoma and vascular invasion will be randomly assigned to receive immunotherapy alone or with particle beam radiation. Researchers will track how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immunotherapy and particle beam radiation therapy
What this could lead to: If successful, this could show that adding particle beam radiation to immunotherapy helps control advanced liver cancer with blood vessel invasion better than immunotherapy alone.
What could go wrong: This is a phase II trial with only 128 participants, so results are preliminary. The combination may not improve survival and could increase side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

National Cancer Center
RECRUITING

Goyang, South Korea
Samsung Medical Center, Seoul
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.